Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
Daria M. Keller, Natasha Ahmed, Hamza Tariq, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 6, pp. 1470-1470
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 3, pp. 212-220
Open Access | Times Cited: 18
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences
Guglielmina Froldi
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 478-478
Open Access | Times Cited: 15
Decongestion in Acute Heart Failure—Time to Rethink and Standardize Current Clinical Practice?
Valentin Bilgeri, Philipp Spitaler, Christian Puelacher, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 311-311
Open Access | Times Cited: 5
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review
Liana Iordan, Laura Gaiță, Romulus Timar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7057-7057
Open Access | Times Cited: 5
Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
Lucia Scisciola, Ugo Chianese, Vicky Caponigro, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 13
Associação entre diabetes e insuficiência cardíaca: mecanismos, fatores de risco e implicações clínicas
Roger Antônio Morais Queiroz, Hanna Victoria Marinho Oliveira Garcia, Geraldo Magela Pereira, et al.
Caderno Pedagógico (2025) Vol. 22, Iss. 1, pp. e13212-e13212
Closed Access
mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Sumit Saha, Xianjun Fang, Christopher D. Green, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15078-15078
Open Access | Times Cited: 10
The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study
Liana Iordan, Sandra Lazăr, Romulus Timar, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 209-209
Open Access
Kidney Outcomes of Systemic Lupus Erythematosus Patients treated with SGLT2 Inhibitors: a national cohort study
Iftach Sagy, Itamar Ben Shitrit, Ran Abuhasira, et al.
Seminars in Arthritis and Rheumatism (2025), pp. 152746-152746
Closed Access
Non-coding RNAs in diabetes mellitus and diabetic cardiovascular disease
Chengshun Li, Dongxu Wang, Ziping Jiang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 15
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Munteanu Madalina Andreea, Swarnkar Surabhi, Răzvan-Ionuț Popescu, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 742-742
Open Access | Times Cited: 9
The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers
Mehmet Emin Demir, Tuba Elif Özler, Özgür Merhametsiz, et al.
International Urology and Nephrology (2023) Vol. 55, Iss. 11, pp. 2989-2999
Open Access | Times Cited: 8
Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity
Matthew Anson, Sizheng Steven Zhao, Hani Essa, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 12, pp. 1259-1265
Open Access | Times Cited: 8
“Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions”
Murali Krishna Moka, D K Sriram, Melvin George
Acta Diabetologica (2024)
Closed Access | Times Cited: 3
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia
Yu Horiuchi, Masahiko Asami, Kazuyuki Yahagi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1670-1670
Open Access | Times Cited: 2
Antidiabetic Advancements In Silico: Pioneering Novel Heterocyclic Derivatives through Computational Design
Anuradha Mehra, Aryan Mehra
Current Signal Transduction Therapy (2024) Vol. 19, Iss. 2
Closed Access | Times Cited: 2
Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials
S. Pescariu, Ahmed Elagez, Balaji Nallapati, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 929-929
Open Access | Times Cited: 2
Diabetes and Heart Failure: A Literature Review, Reflection and Outlook
X.-Y. Li, Xiaoyang Zhou, Ling Gao
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1572-1572
Open Access | Times Cited: 2
Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Angelica Cersosimo, Andrea Drera, Marianna Adamo, et al.
Kidney and Dialysis (2024) Vol. 4, Iss. 4, pp. 184-202
Open Access | Times Cited: 2
Charge transfer based green spectrophotometric method to determine remogliflozin etabonate applying response surface methodology supported with computational studies in pharmaceutical formulations
Sk Manirul Haque, Yunusa Umar, Sirhan Al‐Batty, et al.
Sustainable Chemistry and Pharmacy (2023) Vol. 35, pp. 101193-101193
Closed Access | Times Cited: 5
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
Sha Chen, Cees A. Schumacher, Shirley C.M. van Amersfoorth, et al.
Frontiers in Physiology (2023) Vol. 14
Open Access | Times Cited: 5
Utilization and impact of SLGT2 inhibitors among diabetes patients in a nationally representative survey: Findings from NHANES 2013–2020
Tsung‐Hua Shen, Joel F. Farley
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 11, pp. 108625-108625
Closed Access | Times Cited: 5
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Francesca Romana Prandi, Lucy Barone, Dalgisio Lecis, et al.
Biomolecules (2022) Vol. 12, Iss. 10, pp. 1349-1349
Open Access | Times Cited: 8
Empagliflozin attenuates hypoxia-induced heart failure of zebrafish embryos via influencing MMP13 expression
R Huttunen, A-M Haapanen-Saaristo, Anja Hjelt, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117453-117453
Open Access | Times Cited: 1
Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Veera Ganesh Yerra, Kim A. Connelly
Physiology (2024) Vol. 39, Iss. 6, pp. 412-434
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top